Wednesday, July 8, 2026

biotech · Type 1 Diabetes · Coronavirus · SABS

SAB Biotherapeutics

SAB Biotherapeutics is a biotech organization headquartered in Gaithersburg, USA. It trades on NYSE under ticker SABS. Primary therapeutic focus areas include Type 1 Diabetes, Coronavirus, Influenza A H1N1, Influenza Typ

Gaithersburg, USA HQ
2016 Founded
39 Employees
Public company Type
SABS · NYSE Ticker
Company details
Status
Public
HQ
Gaithersburg, USA
Founded
2016
Employees
39
Programs
8
Drugs
10
Patents
1
Clinical program

SAB-176

Phase 2 · mab · Influenza A H1N1

SAB-176 for Influenza A H1N1 is a Phase 2 program (mab) at SAB Biotherapeutics with 1 ClinicalTrials.gov record(s).

Internal code SAB-176-201

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
SAB Biotherapeutics
Phase
Phase 2
Modality
mab
Indication
Influenza A H1N1
Status
completed
Trials
1